Dec. 2, 2019
CONTACT: Lynn Sutfin, 517-241-2112
LANSING, Mich. – Starting today, the Michigan Department of Health and Human Services (MDHHS) Medical Services Administration has removed prior authorization requirements for medications used to treat opioid use disorder, including buprenorphine.
"The removal of prior authorization for these medications in the Medicaid program will help increase access to treatment for people with opioid use disorders," said Dr. Joneigh Khaldun, chief medical executive and chief deputy for health for MDHHS. "By eliminating this requirement, medical providers will be empowered to help people begin treatment when they are ready and increase their chances of a successful recovery."
Prior authorization is a requirement that physicians must obtain approval from a patient's health care insurer before prescribing a specific medication or to perform a particular operation.
After an in-depth analysis of the prior authorization program, existing literature and lessons learned in other states, MDHHS believes that prior authorization creates substantially more barriers to accessing care for opioid use disorders than protections from misuse of substances.
More on Michimich.com
Medication-assisted treatment, combined with counseling or behavioral therapy, is the gold standard for treating individuals with opioid use disorder, leading to significantly better outcomes. Prior authorization has been removed in 21 states with no data indicating an increased rate of drug diversion.
MDHHS will conduct an evaluation and complete quarterly monitoring of drug utilization claims to assess changes in how the medications are used to treat patients and ensure that the change does not result in any negative impacts.
More information is available in a Frequently Asked Questions document.
For more information on the opioid epidemic and efforts being made by the state to address this issue, visit Michigan.gov/Opioids.
CONTACT: Lynn Sutfin, 517-241-2112
LANSING, Mich. – Starting today, the Michigan Department of Health and Human Services (MDHHS) Medical Services Administration has removed prior authorization requirements for medications used to treat opioid use disorder, including buprenorphine.
"The removal of prior authorization for these medications in the Medicaid program will help increase access to treatment for people with opioid use disorders," said Dr. Joneigh Khaldun, chief medical executive and chief deputy for health for MDHHS. "By eliminating this requirement, medical providers will be empowered to help people begin treatment when they are ready and increase their chances of a successful recovery."
Prior authorization is a requirement that physicians must obtain approval from a patient's health care insurer before prescribing a specific medication or to perform a particular operation.
After an in-depth analysis of the prior authorization program, existing literature and lessons learned in other states, MDHHS believes that prior authorization creates substantially more barriers to accessing care for opioid use disorders than protections from misuse of substances.
More on Michimich.com
- Michigan: M-24/Turrill Road signal in Lapeer to begin flash mode by Dec. 12
- DuraFast Label Company Preparing for Demand for Epson's New CW-C6500 8-inch Color Label Printers
- Thiel College to host cyclists for Bike MS: Escape to the Lake 2020 fundraising event
- Domino's® GPS Delivery Tracking Technology Expanding into Stores Across the U.S.
- The Story of the LUCKY GOLD COIN in the Cake
Medication-assisted treatment, combined with counseling or behavioral therapy, is the gold standard for treating individuals with opioid use disorder, leading to significantly better outcomes. Prior authorization has been removed in 21 states with no data indicating an increased rate of drug diversion.
MDHHS will conduct an evaluation and complete quarterly monitoring of drug utilization claims to assess changes in how the medications are used to treat patients and ensure that the change does not result in any negative impacts.
More information is available in a Frequently Asked Questions document.
For more information on the opioid epidemic and efforts being made by the state to address this issue, visit Michigan.gov/Opioids.
0 Comments
Latest on Michimich.com
- Michigan: MPSC accepts parts of Upper Peninsula Power Co.'s integrated resource plan, recommends changes
- Michigan: MPSC approves $19.9M rate increase for SEMCO Energy Gas Co.
- Michigan: Gov. Whitmer Lowers Flags in Observance of Pearl Harbor Remembrance Day
- Michigan: MI AG Nessel Charges Former Credit Union Teller with Embezzlement from Elderly Customer
- More than 11,000 blind, visually impaired Michiganders receive services over 50-year span
- Michigan: Gov. Whitmer Files Brief in Supreme Court Regarding State Funding of Nonpublic Schools
- Michigan: Community Engagement Advisory Committee for Benton Harbor Area Schools Holding Outreach Meetings
- Gov. Gretchen Whitmer announces new initiative aimed at job training for Michigan vets during two-day Silicon Valley mission
- Michigan: Marijuana Regulatory Agency to Hold Public Meeting in Flint on Monday
- Michigan: Roundabout at Blair Townhall Road added to 2021 M-37 center left-turn lane project
- CEO Coaching International Congratulates Client Synlio on Sale to Boston-Based Building Engines
- Sprawling New Novel, WE OF THE FORSAKEN WORLD, Tackles Themes of Global Connection
- QuiAri Promotes Brad Stewart To Director Of Field Development
- Pilot Trading Expands Its Suite of Broker Integrations by going Live with TradeStation
- Debut Author Karen Wolff's THE GREEN YEARS Is a Compelling Post-WWI Coming-of-age Story
- Right Cars Vehicle Rental announce the appointment of Alison Lee as Customer Service Director
- The Azores - the world's first certified archipelago
- Number of renewable energy installations up by 57% in Michigan in 2018
- Michigan: Strampel Permanently Surrenders License to Practice Medicine; Ordered to Pay $35,000 Fine
- CopyLady Earns ENX Magazine Elite Dealer of the Year Award